01—Abstract
Summary
Summary of the 10-K filed February 27, 2013. Cited figures are marked; the original filing is the authoritative source.
Aflac Incorporated's 2012 10-K filing reveals a company heavily reliant on its Japanese operations, which accounted for 77%a of total revenues and 87% of total assets in 2012.
Despite a challenging global economic environment, Aflac Japan demonstrated robust sales growth, driven significantly by its banking channel partnerships and the WAYS product. In the U.S., Aflac U.S. saw modest premium income growth and continued to expand its broker and group insurance offerings. The company's financial performance showed a substantial increase in net earnings and diluted EPS in 2012 compared to 2011, partly due to lower net realized investment losses.
Aflac continued its commitment to shareholder returns through dividends and share repurchases. Key risks highlighted include exposure to global capital markets, the concentration of business in Japan, and the impact of foreign currency fluctuations, particularly the yen-dollar exchange rate.
02—Key points
Key Highlights
- Aflac Japan remains the dominant revenue and asset driver, with 77% of revenues and 87% of assets in 2012.
- Net earnings increased significantly to $2.9 billion ($6.11/diluted share) in 2012 from $1.9 billion ($4.12/diluted share) in 2011, boosted by lower investment losses and improved operating performance.
- Aflac Japan achieved record annual production in 2012, with a 30.8% increase in yen in new annualized premium sales, largely driven by the bank channel and the WAYS product.
- U.S. operations showed steady growth, with a 5.1% increase in annualized premiums in force and continued development of broker relationships and group insurance products.
- The company repurchased 1.9 million shares of common stock in 2012 and plans to continue share repurchases.
- Key risks include exposure to global economic and capital market conditions, significant concentration in Japan, and foreign currency fluctuation (yen/dollar exchange rate).
- The company's solvency margin ratio in Japan (Aflac Japan) was strong at 669.1% under new standards as of December 31, 2012.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2012filed February 27, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $25.36B$22.17B | +14.4% |
| SG&A Expenses | $2.42B$2.34B | +3.4% |
| Operating Income | $4.66B$4.50B | +3.5% |
| Interest Expense | $261.00M$196.00M | +33.2% |
| Net Income | $2.87B$1.94B | +48.0% |
| EPS (Basic) | $3.07$2.08 | +47.6% |
| EPS (Diluted) | $3.06$2.06 | +48.3% |
| Shares Outstanding (Basic) | 933.74M933.04M | +0.1% |
| Shares Outstanding (Diluted) | 938.57M938.74M | 0.0% |
05—Questions
Frequently Asked Questions
What is Aflac's primary geographic revenue source?
Aflac's primary geographic revenue source is Japan. In 2012, Aflac Japan's operations accounted for 77% of the company's total revenues.
How did Aflac's net earnings perform in 2012 compared to 2011?
Aflac's net earnings significantly increased in 2012 to $2.9 billion, or $6.11 per diluted share, compared to $1.9 billion, or $4.12 per diluted share, in 2011. This improvement was driven by lower net realized investment losses and strong operational performance, particularly from Aflac Japan.
What are the main risks Aflac faces according to the filing?
Aflac faces several key risks, including challenging global capital markets and economic conditions, significant business concentration in Japan, foreign currency fluctuations (especially the yen-dollar exchange rate), and the potential for defaults or downgrades in its investment portfolio.
What is the outlook for Aflac Japan's sales in 2013?
Aflac Japan achieved record sales in 2012 and is expected to see continued sales growth in 2013, with an objective for flat to up 5% growth in third sector (cancer and medical) products. However, comparisons to 2012's strong performance are expected to be more difficult.
06—Continue